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Dual Controls, p-Value Plots, and the
Multiple Testing Issue in Carcinogenicity
Studies
by Murray R. Selwyn*
The interpretation ofstatistically significant findings in acarcinogenicity study is difficult, in part because
ofthe large number ofstatistical tests conducted. Some scientists who believe that the false positive rates
in these experiments are unreasonably large often suggest that the use ofmultiple control groups will pro-
vide important insight into the operational false positive rates.
The purpose ofthis paper is 2-fold: to present results from two carcinogenicity studies with dual control
groups, and to present and illustrate a new graphical technique potentially useful in the analysis andinterpre-
tation oftumor data from carcinogenicity studies. The experimental data analyzed show that statistically
significant differences between identically treated groups will occurwith regular frequency. Such data, how-
ever, do not provide strong evidence of extrabinomial variation in tumor rates.
Thep-value plot is advocated as a graphical method that can be used to assess visually the ensemble ofp
values for neoplasm data from an entire study. This technique is then illustrated using several examples.
Through computer simulation, we presentp-value plots generated with and without treatment effects pres-
ent. On average, theplots looksubstantially differentdepending on the presence or absence ofan effect. We
also evaluate decision rules motivated by thep-value plots. Such rules appear to have good power to detect
treatment effects (i.e., have low false negative rates) while still controlling false positive rates.
Introduction
One ofthe most difficult issues associated with the in-
terpretation ofresults from a carcinogenicity study in ex-
perimental animals is the question of biological versus
statistical significance. Suppose, for example, that a
statistically significant increasing trend in tumor rates is
detected for one or two sites among a large number of
such sites examinedmicroscopically. Can we conclude that
these are real effects or are thefindings simply a chance
event?
This issue relates directly to the question offalseposi-
tive rates in these studies, an issue that has been dis-
cussed and debated in the statistical and toxicological
literaturefor decades. Thebasic argumentthattheoverall
or experiment-wise error rate may be unreasonablyhigh
(1) follows from a simple probability calculation. IfMin-
dependent statistical tests are conducted, each at the
p = 0.05 level, then the probability ofatleast one signif-
icantfinding is 1 - 0.95M. ForM = 10this overallproba-
bility is 0.40 and for M = 40, the probability is 0.87. In
a carcinogenicity study, where 30 to 40 tissue or organ
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sitesmaybe examined forbothmales andfemales, there
is thepotentialforahighfalse positive rate (themultiplic-
ity problem).
The actualfalsepositiveratein acarcinogenicity study
maynotbe nearlyashigh asindicatedbythe aboveprob-
ability calculation, however. As several authors(2-4)have
pointed out, most scientific decisions are not based on a
single statistically significant result atthe 0.05level, and
further, as notedby Haseman (4), many statistical tests,
in fact, operate below their nominal levels. By studying
historical tumor rates from 25 studies conducted by the
National Tbxicology Program (NTP), Haseman (4) con-
cluded that a statistical decision rule that approximated
the NTPbiological decisionprocess couldbe formulated
as follows: Declare a positive finding ifthe p value com-
paringthe high dose to controls is less than 0.01 for com-
mon tumors (greater than 1% historical spontaneous rate)
or ifthe p value is less than 0.05 for uncommon tumors.
(Haseman's calculations of false positive rates used
Fisher's exact test comparing the high dose to controls.
Sample sizes were 50 per group.)
The applicability ofHaseman's results to awiderscope
of situations depends on how typical the NTP data are.
In addition, one of the critical assumptions (which is
generally made when analyzing unadjusted or lifetime
tumorincidence data)is thatthetumorcounts arebinomi-M. R. SELWYN
ally distributed. In a typical carcinogenicity bioassay de-
sign with a single control group and treated groups at
several exposure levels ofachemical [e.g., IARC (5)], the
binomial assumption cannot be verified. In contrast,
studies with replicate groups can be used to assess the
binomial assumption. Haseman et al. (6) present results
from a set of 18 color additive studies, each employing a
dual control group design. In brief, they found no evi-
dence ofextrabinomial, within-study variability in these
studies. They again reaffirmed, however, the idea that
more stringent evidence than a single p < 0.05 for com-
mon tumors should be required forbiological significance;
otherwise, the experiment-wise false positive rate could
be unacceptably high.
Haseman et al. are understandably cautious in gener-
alizingtheir results. Therefore, there is continued interest
in the results ofstudies with dual controls. The purpose
ofthepresentpaperis2-fold: topresentfindingsfromtwo
studies designed with dual control groups [although the
datafrom these studies are on amuch smaller scale than
the data analyzed by Haseman et al. (4)], and to present
and illustrate a newgraphical technique potentially use-
ful in the analysis and interpretation oftumor datafrom
rodent carcinogenicity studies. Our concern throughout
relates to the false positive rate in these studies, applica-
ble statistical procedures, andthe implications ofdecision
rules on statistical power(or equivalently the false nega-
tive rate). Our goal is to consider statistical approaches
that will be helpful to other scientists in their biological
interpretation of tumor data from these studies.
Studies with Dual Control Groups
The rationale for designing carcinogenicity studies with
dual control groups is to provide abetween-groups com-
parison that is not confounded with potential treatment
effects. Any twogroupsthatdiffer interms ofexperimen-
tal conditions would notprovide such a comparison. For
suchgroups, differences inresponse couldpotentiallybe
due to the different experimental conditions. As the two
control groups are treated identically throughout the
study, any differences in responses must simply be due
to chance. Ifthey differ more frequently than would be
explainable according to the standard binomial model,
thenthispresents some evidence that the standardmodel
may not hold. In such cases, statistical procedures need
to be modified to take into account this extrabinomial var-
iation.
In this section, we present and analyze a subset ofthe
results from two studies, one inrats and one inmice, with
dual control groups. The first study was conducted in
CD-1 mice with two vehicle control groups(control group
1 and control group 2), and three other groups fed dose
levels of25, 100, and400mg/kg/day ofthe chemical(chem-
ical 1)inthe dietfor25 months. At the startoftheexperi-
ment, there were 100 mice in each ofthe five treatment
groups foreach sex. We concentratehere onthe compar-
ison between the two control groups in the experiment.
Table 1 presents the results ofstatistical analyses with
Fisher's exacttest comparingthe tumorrates in the two
control groups. Notice that among the 29 tumor
types/sites analyzed, three comparisons are significant at
the 0.05 level. When group 1 is viewed as the treated
group, it has a significantly higher rate ofreticulum cell
sarcomas in males (p = 0.032). When group 2 is consid-
ered as atreatedgroup, two comparisons are significant:
lymphosarcomas in females (p = 0.032) and total blood
vessel tumors in males (p = 0.008). Do these results pre-
sent strong evidence of extrabinomial variation?
To address this question, we performed calculations of
false positive rates in the same manner as did Haseman
et al. (6) in theiranalysis ofthe 18 color additive studies.
Basically, these authors calculated twotypes offalseposi-
tive rates: conditional and unconditional. Conditional
rates are calculated assuming that the total number of
tumors inthe twogroupsisfixed. Forexample, ifone ob-
serves 5/100 ingroup 1 and 7/100 ingroup2, then the to-
tal number oftumors in both groups is 12. We can then
calculate the probability ofall statistically significant out-
comesusing Fisher's exact test at the 0.05level condition-
ally, given a total of12 tumors. The unconditional method
simply uses the twoproportions to estimate the common
tumor rate, which would be 12/200 = 0.06 for the exam-
ple. Given this asthe spontaneous rate in eachgroup, we
can again calculate the probability ofall statistically sig-
nificant outcomes.
Table 2 presents estimated conditional and uncondi-
tional false positive rates for each ofthe 29 tumor types
considered in Table 1. Notice that, as observedby Hase-
man(4), tumortypeswithlowrates have negligible false
positive rates, and therefore contribute minimally to the
overall (experiment-wise) false positive rate. The condi-
tional rates calculated withgroup 1 as the treatedgroup
and with group 2 as the treated group are not identical
because ofoccasional differences in denominators. Some-
times these differences in false positive rates are ap-
preciable (Table 2). Such differences are due to the dis-
crete nature of the counts used in the test and the fact
that evenwith denominators ofalmost 100, theprobabil-
ity distributions take large jumps. Moreover, there are
sometimesconsiderable differencesbetweenfalsepositive
rates calculated conditionally and unconditionally(Table
2), again because ofthe discrete nature ofthe data. The
unconditional rates increase smoothly with the back-
ground tumor rates observed here.
Usingthe unconditional falsepositive rates andassum-
ingindependence acrossthe29 sites(as did Haseman), we
calculate the following probabilities:
Prob [no significant results at 0.05 level] = 0.676.
Prob [one significant result at 0.05 level] = 0.269.
Prob [two significant results at 0.05 level] = 0.050.
Prob [three or more significant results
at 0.05 level] = 0.006.
Thusthe overallfalse positive rate is 1 - 0.676 = 0.324,
andthe chance ofgettingatleasttwopositive results are
0.050 + 0.006 = 0.056. Even though we have observed
two significant results comparinggroup 2(as treated) to
group 1 as control, the probability of this occurring is
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Table 1. Comparison ofthe dual control groups in the mouse study with chemical 1.
p values from Fisher's exact test
Tumor type Control group 1 Control group 2 Group 1 as treated Group 2 as treated
Females
Hepatocellular carcinoma 0/99 0/98 1.000 1.000
Total hepatocellular tumors 5/99 6/98 0.737 0.493
Uterus: adenocarcinoma 3/98 4/98 0.778 0.500
Uterus: leiomyoma 2/98 3/98 0.816 0.500
Uterus: leiomyosarcoma 1/98 1/98 0.751 0.751
Uterus: granular cell tumor 1/98 0/98 0.500 1.000
Uterus: sarcoma 0/98 1/98 1.000 0.500
Uterus: squamous cell carcinoma 0/98 0/98 1.000 1.000
Vagina: squamous cell carcinoma 1/91 0/90 0.503 1.000
Ovary: granulosa cell tumor 1/96 0/89 0.519 1.000
Ovary: luteoma 0/96 0/89 1.000 1.000
Ovary: papillary cystadenoma 3/96 4/89 0.808 0.458
Hemangiosarcoma: all sites 6/100 5/100 0.731 0.500
Total blood vessel tumors 7/100 13/100 0.952 0.119
Lymphosarcoma 17/100 29/100 0.986 0.032
Granulocytic leukemia 1/100 0/100 0.500 1.000
Mammary gland: adenocarcinoma 1/100 2/100 0.877 0.500
Stomach: adenoma 0/96 1/96 1.000 0.500
Nose: odontoma 1/83 0/84 0.497 1.000
Males
Hepatocellular carcinoma 10/99 10/100 0.584 0.602
Total hepatocellular tumors 19/99 19/100 0.558 0.585
Lung: carcinoma 9/100 9/100 0.597 0.597
Total lung tumors 13/100 16/100 0.789 0.344
Hemangiosarcoma: all sites 3/100 8/100 0.971 0.107
Total blood vessel tumors 3/100 13/100 0.999 0.008
Reticulum cell sarcoma 7/100 1/100 0.032 0.997
Stomach: papilloma 1/98 0/99 0.498 1.000
Nose: odontoma 3/80 4/83 0.763 0.521
Testis: gonadal stromal tumor 1/100 3/100 0.939 0.311
0.056, assumingbinomial variation. Hence, these data do
not exhibit strong evidence of extrabinomial variation.
When group 1 is viewed as treated, the probability cal-
culation for one ormore positives is 0.324. In the second
studywith chemical 1 inSprague-Dawley rats, none of14
comparisons between the dual controls resulted in a
statistically significant (p < 0.05) difference in either
directionusing Fisher's exact test. Thus, evidence ofex-
trabinomial variation is trulylackinginthese two studies.
For the mouse study, when all tests are performed at
the 0.05level, the overall error rate of32% is unaccepta-
bly high. Thisfindingis consistent with thatofHaseman
(4), who concludes that the overall error rate is too high
ifall tests are conducted at the 0.05 level. Haseman con-
siderstesting atthe 0.01 levelfor common tumors and at
the 0.05 level for rare tumors. But assumingthat the ob-
served spontaneous rate fortotal blood vessel tumors in
male mice (16/200 = 0.08) is unbiased, the observed p
value of0.008 would lead us to conclude that the group
2 effect is tumorigenic using p < 0.01.
Thus, eventhough these data sets do notprovide strong
evidence ofextrabinomialvariation, they do reinforce the
ideathatfalsepositives continue tobe a substantial prob-
lem in carcinogenicity studies.
p-Value Plot as a Diagnostic Tool
As noted by a number ofauthors (7,8), considerations
other than p values alone bear upon the question ofcar-
cinogenicity in aparticular instance. As stated inthe 1980
IARC monograph (7):
"P-values are objectivefacts,butunless ap-value is veryextreme,
the proper use of it in the light of other infornation to decide
whether or notthe test agentreallyis carcinogenic involves sub-
jective judgment."
Haseman (4)arguesthatadditionalfactors to be consid-
ered should include the historical control tumor rate for
the tumor in question, the survival histories ofthe con-
trol and treatedgroups, dose-dependence and similarity
offindings amongdifferent sexes and species, andbiolog-
ical plausibility in light of earlier toxicological studies,
mutagenicity findings, etc.
Alarge part ofthe role ofthe statistician is to provide
objective means for interpreting data and results to as-
sist in making subjectivejudgments. In this regard, we
highlight three areas inwhich statistical techniques may
be most useful.
Thefirstis theformalapplication ofstatisticalmethods,
incorporatinghistorical controlsintothe analysisoftumor
data. Several methods are currently available (9,10).
These methods have been found to be quite informative
whentumorrates arelowandthe potential dose-response
is low enough to be uncertain.
The second area involves the evaluation ofthe results
in one sex (e.g., males) while taking into account the
results in the other sex (females). Thus, one could treat
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Table 2. Estimated false positive rates when comparing the two control groups in the mouse study with chemical 1.a
Unconditional false Conditional false positive rates
Tumor type positive rateb Group 1 as treated Group 2 as treated
Females
Hepatocellular carcinoma 0.000 0.000 0.000
Total hepatocellular tumors 0.022 0.030 0.028
Uterus: adenocarcinoma 0.017 0.007 0.007
Uterus: leiomyoma 0.012 0.030 0.030
Uterus: leiomyosarcoma 0.001 0.000 0.000
Uterus: granular cell tumor 0.000 0.000 0.000
Uterus: sarcoma 0.000 0.000 0.000
Uterus: squamous cell carcinoma 0.000 0.000 0.000
Vagina: squamous cell carcinoma 0.000 0.000 0.000
Ovary: granulosa cell tumor 0.000 0.000 0.000
Ovary: luteoma 0.000 0.000 0.000
Ovary: papillary cystadenoma 0.017 0.009 0.048
Hemangiosarcoma: all sites 0.022 0.029 0.029
Total blood vessel tumors 0.031 0.049 0.049
Lymphosarcoma 0.036 0.032 0.032
Granulocytic leukemia 0.000 0.000 0.000
Mammary gland: adenocarcinoma 0.004 0.000 0.000
Stomach: adenoma 0.000 0.000 0.000
Nose: odontoma 0.000 0.000 0.000
Males
Hepatocellular carcinoma 0.031 0.046 0.017
Total hepatocellular tumors 0.035 0.048 0.025
Lung: carcinoma 0.030 0.041 0.041
Total lung tumors 0.034 0.022 0.022
Hemagiosarcoma: all sites 0.022 0.029 0.029
Total blood vessel tumors 0.028 0.033 0.033
Reticulum cell sarcoma 0.018 0.032 0.032
Stomach: papilloma 0.000 0.000 0.000
Nose: odontoma 0.019 0.006 0.008
Testis: gonadal stromal tumor 0.008 0.000 0.000
'All tests at the 0.05 level.
bCommon tumor rate estimated from pooled incidence. Assumes 100 animals per group.
responses of(0/50,3/50, 6/50,8/50) inmales differently de-
pending on whether one has observed (8/50, 6/50, 4/50,
7/50) or(1/50,3/30,5/50, 6/50) infemales. This idea is cur-
rently beingpursued in terms ofresearch on appropriate
statistical methods.
The third idea relates to techniques to graphically dis-
play and evaluate the ensemble ofp values forneoplasm
data from an entire study. Our methods are similar in
spirit, but less elaborate than those recently proposedby
Meng and Dempster (11). In this section, we discuss the
use ofp-value plots as an informal graphical method for
assessing the overall carcinogenicity of a chemical.
We assume that appropriate statistical analyses have al-
ready been conducted and that p values associated with
potential treatment effects are available from a number
of tumor types/sites. Given this set of p values, our ap-
proach proceeds as follows:
* Instead of working with the p values (p's), it is
more convenient to work with the 1-p's. Thus a p
value of0.01 has a corresponding 1-p value of0.99.
The rationale forworkingwith the 1-p's instead of
p's is that data analysts (statisticians, scientists)
may be more comfortable investigatinginteresting
large values (e.g., outliers, right-skewed distribu-
tions) rather than small ones.
* The 1-p's are ordered from smallest to largest.
Large values of 1-p, ofcourse, correspond to small
p values. Assuming that the p values areindepen-
dent(not quite true because ofthe dependence be-
tween tumortypes) and each is uniformly distrib-
uted on the interval [0,1] (also not quite true
because ofthe discretenessof sometests), thenthe
ordered 1-p's each follow a beta distribution. The
expectations andpercentiles ofthisapproximating
distribution canbe obtained. Theexpectationofthe
ith largest value is i/(n + 1). We obtained percen-
tiles for each ordered 1-p using the BETAINV
function in SASR. All values are plotted versus
equally spaced scores. In practice, it is probably
easiest to usei/(n + 1). Then theexpected line has
unit slope.
* Each observed 1-p isplotted along with its expec-
tation andpercentiles versusequallyspaced scores.
Despite the fact that theassumptions above do not
strictly hold, this will give an informal indication
about the p valuesjointly.
* Of particular importance are the most extreme
(highest) 1-p values. For example, are any outside
the 2.5 to 97.5%envelope? Do thehighest ones all
lie above their expected values?
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Tb illustrate this idea, we show in Figure 1 the p values
from Fisher's exact test ofTable 1 using control group 2
as treated. Notice that there are a large number of p
values identically equal to 1 corresponding to the many
1-p values of0 displayed in the lower left portion ofthe
graph. The observed 1-p'sgenerally lie below their expec-
tations, indicating the conservative nature ofFisher's ex-
act test. Also, one can see the step-function form of the
1-p curve illustrating the discreteness of the data.
Ib adjust forthese factors, we eliminate p values equal
to 1. (Inpractice, one would also eliminates sites with only
one tumor because of the discreteness ofp-value distri-
bution.) In Figure 2, we display the resulting 1-p values
with expectations and percentiles recomputed accord-
inglyforthe reduced set. Note that the test does not ap-
pear as conservative as in Figure 1, as many of the 1-p
values are now above their expectations. Ofparticular in-
terest are the low p values. We can compare the three
lowest values to their expectations and to the 2.5% point
(envelope), as shown in Table 3.
As can also be seen from Figure 2, the two lowest p
values are below their expected values, but are consider-
ably above the 2.5% values from their respective distri-
butions. (Recall that we plot 1-p's rather thanp's, so that
therelevantpart ofFigure 2isintheupper-right corner).
Figure 3 presents p values from trend tests [eitherthe
Cochran-Armitage test (12,13) or an exact trend test of
Bickis andKrewski(14)] comparingthe treated groups in
the mouse study with chemical 1 to the pooled control
group (pool of control group 1 and control group 2). p
values of 1 have been eliminated. Observe that the 1-p
valuesfrom these tests fluctuate around the expected line
and lie totally within the (2.5 to 97.5%) envelope, thus in-
dicatinggeneral conformance with the assumptions ofthe
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FIGURE 1. Chemical 1 mouse study: p values (Fisher's exact test, group
2 as treated). Observed 1-p(0), expected values (*), 2.5% envelope (A),
and 97.5% envelope (A) versus equally spaced scores [iI(n + 1)].
Table 3.
values (*), 2.5% envelope (-), and 97.5% envelope (U) versus equally
spaced scores [iI(n + 1)].
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FIGURE 3. Chemical 1 mouse study: p values from trend tests (p values
of 1 eliminated). Observed i-p(0), expected values (*), 2.5% envelope
(A), and 97.5% envelope (U) versus equally spaced scores [il(n + 1)]. () ld9.%evlp(Avesseulyspaced scores [il(n+ 1)].
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FIGURE Chemical mouse study: p values from trend tests (p values
of 1 eliminated). Observed i-p (0), expected values (*), 2.5% envelope
(A), and 97.5% envelope (U) versus equally spaced scores [iI(n + 1)].
plotting procedure described. As the smallest p value
from these trend tests is 0.09, there is no evidence ofin-
creasing tumor rates as a result offeeding the chemical
to mice.
Our final example is from a chronic feeding study in
mice with chemical 2. Figure 4 displays the observed 1-p
Observed p value Expected p value Lower 2.5 percentile
0.008 0.048 0.001
0.032 0.095 0.012
0.107 0.143 0.032
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values, theirexpectations, andthe (2.5to 97.5%)envelope.
Again, p values of 1 have been eliminated prior to this
analysis. Including all results forboth males andfemales,
a total of42 individual trend tests have been conducted.
The observed i-p's fluctuate about their expected values.
The three lowest p values are shown in Table 4.
Despite thefact that the smallestpvalue amongthe 42
is0.01, this value is not veryfarfromits expectation and
considerably higherthan the 2.5% value. The other small
p values are not unusual at all.
p-Value Plots: Computer-Simulated
Data
The examples intheprevious section illustrate the con-
cept that small p values can easily arise due to chance.
Theirpresence is consistentwith anoverallnull hypothe-
sis ofnotreatment-related effects, as shownbythepvalue
plots. But is the converse true? When there are real treat-
ment effects, dop-value plots appear different than they
do without such effects present?
In an effort to shed some light on these questions, we
conducted several computer simulation studies where we
generated binomially distributed data (using the SAS
function RANBIN), statistically analyzed them, and
produced correspondingp value plots. We provide the de-
tailsbehind the simulations and ourresults inthis section.
The statistical procedure used throughout was the
Cochran-Armitage (CA) trend test (12,13). For the first
set ofsimulations, wegenerated dataconsistent with the
null hypothesis ofno treatment effect. Initially 5000 in-
dependent sets were generated, each set consisting ofa
control and three nonzero dose groups of size 60 (doses
1, 2, 3). Ofthese, 1000 were generated with a spontane-
ous tumorrate of2%, 2000 weregenerated with arate of
5%, and the remaining 2000were generated with a spon-
taneous rate of10%. Withthese 5000 cases as input data
to the CA test, we calculated rejection rates ofthe test
for both a continuity-corrected and noncontinuity-
corrected version. The results are shown in Table 5.
Thus, with spontaneous rates of 10% or less, the non-
continuity correctedversionofthe CAtestoperates close
to its nominal level. When tumor rates are low (i.e., 2%),
the testis somewhat conservative, butnotnearly as con-
Table 4.
Observed p Expected p Lower 2.5 percentile
0.010 0.023 0.001
0.048 0.047 0.006
0.056 0.070 0.015
servative as Fisher's exact testwouldbe in the same sit-
uation. Inwhatfollows we continue to work withthe CA
test without continuity correction.
The 5000 p values from this null case were randomly
grouped into 200 sets with 25 tumor types/sites per set,
such that, within each set, 5 came from the 2% back-
ground rate, 10 came from the 5% background rate, and
the other 10 came from the 10% background rate. This
gave us a collection of 200 studies, each with 25 tumor
types/sites per study. Within each study, the p values
were ordered from smallest to largest. We then inves-
tigated the distributions ofthe order statistics obtained
in this way.
Inparticular, we examinedthe25thpercentile (overthe
200 studies), median (overthe 200 studies), and 75th per-
centile (overthe 200 studies) ofthe ordered p valuesfrom
the 200 studies. These were plotted along with expected
values and the (2.5 to 97.5%) envelope ofthe p-value plot
as defined earlier. Figure 5 displays the results. Notice
that the median ofthe 200 studies matches closely with
the expected values and that the 25th and 75th percen-
tile curves both lie well within the envelope.
A second setofindependent simulations wasgenerated
to represent the situation where treatment effects were
present. Themethodofgeneratingthe data was the same
asforthe null case, except attwo sites perstudy. Instead
ofcountsgenerated at a constant5%rate, countsforthese
two sites weregenerated asindependentbinomials with
rates 0.005, 0.025, 0.075, and 0.100, respectively, in the
four groups (doses 0, 1, 2, 3). Cochran-Armitage test
statistics and corresponding p values were calculated as
described.
0.9
EQUALLY SPACED SCORES
FIGURE 5. Simulation results, case 1 (no treatment effects). Twrenty-fifth
percentile of simulation runs ([O), median of simulation runs (*), 75th
percentile of simulation runs (-), 2.5% envelope (-), and 97.5% enve-
lope (O) versus equally spaced scores [i/(n + 1)].
Table 5.
Number No continuity correction With continuity correction
Background of Proportion rejected Proportion rejected
rate cases (a = 0.05) (a = 0.01) (a = 0.05) (a = 0.01)
0.02 1000 0.035 0.005 0.014 0.004
0.05 2000 0.052 0.006 0.035 0.005
0.10 2000 0.053 0.012 0.039 0.008
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We again examined the 25th percentile, median, and
75th percentiles from the ordered p values for the 200
studies. Figure 6 shows avery differentpatternfromthe
one presented in Figure 5. Although the lower left por-
tion ofFigure 6looks similar to Figure 5, all three curves
from the simulated datalie above the expected values in
the right portion ofthe figure (corresponding to small p
values orlarge 1-p values). For thelargest 1-p values, all
the curves are close to the upper envelope with the me-
dian curve beingalmostcoincident atthe two largest 1-p
values (smallest p values).
Thus, we see that, at leastinthe longrun,p-value plots
generated withtreatment effects present dolooksubstan-
tially different from those produced under the null case.
Theoretically then, they can be used informally to help
distinguish true positive results from false positives.
Decision Rules Based on p-Value
Plots
We can furtherusethe simulated datapresented inthe
previous section to evaluate various decision rules in
terms ofbothlevel andpower. One such decisionrule(call
it CA01)would be analogous to the one studied by Hase-
man (4), i.e., declare a positive finding if the smallest p
value is less than 0.01. (We assume here that all tumors
are common tumors.)
In addition, we can consider several decision rules
based on whether one or more of the largest 1-p values
lies above a suitably chosen upper envelope. We have
studied both the 97.5%(A) and 95%(B) envelopes and
based decision rules on the 1, 2, or 3 largest 1-p values.
Thus, the decision rule B3 will declare apositive finding
ifany one ofthe three largest 1-p values exceeds the 95%
envelope value.
Results from the first simulation case with no
treatment-related effects give us information on level.
Results fromthe second simulation casegive us informa-
tion on power. These are summarized in Table 6.
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FIGURE 6. Simulation results, case 2 (treatment effects at two sites).
Twenty-fifthpercentile ofsimulation runs([), median ofsimulation
runs (*), 75th percentile ofsimulation runs (@), 2.5% envelope (A),
and 97.5% envelope (U) versus equally spaced scores [i/(n + 1)].
Table 6. Rejection rates (percent).
Decision Simulation 1 Simulation 2
rule (No treatment effects) (Treatment effects present)
CAO1 19 91
Al 0.5 51.5
A2 2.5 68.5
A3 4.5 71
Bi 2 68
B2 6 82.5
B3 8 85.5
InTable 6, one can seethetraditionaltrade-offbetween
level and power. Increased power comes only at the ex-
pense of increasing the experiment-wise false positive
rate. For this example, it appears that rule B2 provides
a good compromise between level and power. With 25 p
valuesintheplot, rule B2 declares apositivefindingifthe
smallestp value is less than 0.002 or ifthe next smallest
p value isless than 0.014. Simes (15) studies aprocedure
with decision rule rejecting ifthe ith smallest p value is
lessthania/N, where Nisthe numberoftests. Heproves
that this procedure has an overall type I error rate of a
when the tests are independent.
Conclusions and Discussion
From our analysis ofthe mouse study data with chem-
ical 1, we see that statistically significant results can arise
due to chance. These data do not, however, provide over-
whelming evidence ofextrabinomial variation, although
such an hypothesis cannot be rejected, either. As Hase-
man and colleaguespoint out(6), such datareinforce the
idea of cautiously interpreting statistically significant
results. Even the use ofthe more conservative decision
rule based onp < 0.01 may not be conservative enough
for some data sets.
We have developed andadvocatedthep-valueplot as an
aid in decision-making for carcinogenicity studies. These
plots are useful diagnostic tools to informally assess the
overall treatment-related effects ofthe experimental com-
pound. Whenmany statistical tests havebeenmade, this
fact isautomaticallyincorporated. Theplotseasilyexhibit
the conservative nature ofsome tests(contrast, for exam-
ple, Fig. 1 withFigs. 3 and4). Byeliminatingresultsfrom
testswithp valuesequal to 1 (orforwhichthe total num-
beroftumors in allgroups isvery low), the observed 1-p
values will often fluctuate about their expected values,
thus eliminatingpotential bias from the procedure. The
plots can distinguish casesinwhich treatment effects are
present from the null case (compare Figs. 5 and 6).
Through the use of a limited set of computer simula-
tions, we have evaluated several decisionrules. With adis-
tribution ofspontaneous tumorrates considerablyhigher
than those from the 25 NTP studies reviewed by Hase-
man, and with the Cochran-Armitage trend test instead
ofthe more conservative Fisher's test, we saw the rule
using p < 0.01 had a false positive rate of 19%. In con-
trast, usingrules constructedfromp-valueplots, wewere
able toreducethisrate toacceptable levels. Ofcourse,this
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resulted in a slight loss in power to detect treatment-
related effects.
Although itmay appear that ourfindings are inconsis-
tentwiththose ofHaseman, this isnot so. The historical
control tumor rates reported in Haseman (4) contained
many low rates. Nine ofthe 27 type/sites had rates less
than2%inratsandseventeenofthe27hadrateslessthan
2% inmice. Hadthese ratesbeen higher, the overallfalse
positive rates reported by Haseman would have been
greater. Second, Haseman's analysis was based on
Fisher's exact test, which is very conservative, regardless
ofthe background rate. In contrast, we showed that the
Cochran-Armitage trend test operates close to its nomi-
nal level when the spontaneous tumor rate is in the 5 to
10% range. Thus, our studies are complementary rather
than contrary to those of Haseman.
Because hypothesis testing seems to be the most com-
monstatistical approach tothe analysis ofdatafrom car-
cinogenicity studies, we believe that it is therefore most
appropriate (in the spirit of the Neyman-Pearson ap-
proach to hypothesis testing) to first control the Type I
errorrate inthese studies. Byemploying statistical tech-
niquesthat control the overallfalse positive rate, such as
those based onp-value plots orother methods ofadjust-
ment (11,16,17), this goal can be achieved. Several such
decisionrules have beenproposed inthispaperandevalu-
ated in the limited set of simulation studies conducted.
Other such rules can easily be contemplated. Their
properties canfurtherbe investigated under avariety of
conditions, again with computer simulation.
Themain advantage ofp-valueplotsisthattheyprovide
the statistician and toxicologist with a simple way to
visually summarize the results of numerous statistical
tests and compare the p values obtained to those that
wouldbeexpectedinthe absence ofcompound-related ef-
fects. By examining the shape ofthe observed 1-p curve
as well as its largest values, information about the over-
alleffectsoftreatment maybe deduced. Thus, webelieve
that suchgraphical evaluations ofdatamayserve asause-
ful tool in interpreting results from carcinogenicity
studies. The final decision process, however, needs to be
an interdisciplinary effort with input from pathologists,
toxicologists, and statisticians (8).
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